Skip to main content
Year archive

PERCHERON THERAPEUTICS LIMITED — 2016 filings

All 38 regulatory filings released by PERCHERON THERAPEUTICS LIMITED (PER) in 2016, sourced directly from the official regulator.

38 Filings
2016 Period
2016 filings (38)
Filing Released Lang
Change of Director's Interest Notice - (RM, MD, GM, WG) 8 pages 60.8KB
Director's Dealing
2016-12-20 English
Results of Rights and Bonus Issue 1 page 360.3KB
Capital/Financing Update
2016-12-19 English
Appendix 3B - Issue of Securities 15 pages 306.8KB
Capital/Financing Update
2016-12-19 English
Appendix 3C 3 pages 26.8KB
Transaction in Own Shares
2016-12-07 English
Change of Director's Interest Notice (RM) 2 pages 22.5KB
Director's Dealing
2016-12-04 English
Bonus and New Options Offer Prospectus 44 pages 253.4KB
Share Issue/Capital Change
2016-11-28 English
Appendix 3B 13 pages 127.5KB
Capital/Financing Update
2016-11-28 English
Receipt of R&D Tax Incentive payment 1 page 17.9KB
Regulatory Filings
2016-11-14 English
AGM Presentation and Questions on notice 18 pages 4.3MB
AGM Information
2016-11-09 English
Results of Annual General Meeting 2 pages 120.5KB
Declaration of Voting Results & Voting Rights Announcements
2016-11-09 English
ATL1102 for Multiple Sclerosis - Progress Update 2 pages 32.1KB
Capital/Financing Update
2016-11-03 English
Appendix 4G - Corporate Governance Statement 13 pages 133.3KB
Governance Information
2016-11-02 English
Appendix 4C - quarterly 5 pages 193.8KB
Interim / Quarterly Report
2016-10-30 English
Change of Director's Interest Notice (WG) 2 pages 22.9KB
Director's Dealing
2016-10-18 English
ATL1103 Higher Dose Study 2 pages 50.4KB
Regulatory Filings
2016-10-10 English
Notice of Annual General Meeting/Proxy Form/Annual Report 91 pages 3.5MB
AGM Information
2016-10-10 English
Less Than Marketable Parcel Share Sale Program 7 pages 77.7KB
Capital/Financing Update
2016-10-10 English
Capital Management Initiatives - Update 2 pages 340.4KB
Capital/Financing Update
2016-10-10 English
Change of Director's Interest Notice (GP) 2 pages 22.8KB
Director's Dealing
2016-09-06 English
Company Update 1 page 21.7KB
Regulatory Filings
2016-08-25 English
Preliminary Final Report 68 pages 529.6KB
Annual Report
2016-08-24 English
Positive Results Achieved from ATL1103 Higher Dose Study 3 pages 82.4KB
Capital/Financing Update
2016-07-26 English
Appendix 4C - quarterly 5 pages 39.6KB
Interim / Quarterly Report
2016-07-17 English
ATL1103 Patent Update 2 pages 26.0KB
Regulatory Filings
2016-07-12 English
ATL1103 Granted Orphan Drug Designation in Europe 2 pages 26.2KB
Regulatory Filings
2016-06-27 English
ATL1102 for Multiple Sclerosis - Update 3 pages 32.1KB
Regulatory Filings
2016-06-16 English
Antisense Technology Update 1 page 23.1KB
Regulatory Filings
2016-05-31 English
Company Strategy Update 2 pages 35.7KB
Capital/Financing Update
2016-05-23 English
Orphan Drug designation from FDA for ATL1103 in Acromegaly 2 pages 30.4KB
Regulatory Filings
2016-05-11 English
ATL1103 Higher Dose Study - Update 2 pages 30.7KB
Regulatory Filings
2016-05-08 English
ATL1103 Deed of Settlement, Termination and Transfer 1
Capital/Financing Update
2016-04-28 English
Appendix 4C - quarterly 5 pages 39.3KB
Interim / Quarterly Report
2016-04-21 English
COR-004/ATL1103 Project Update 5 pages 139.0KB
Capital/Financing Update
2016-03-08 English
Trading Halt 1 page 223.9KB
Regulatory Filings
2016-03-06 English
Trading Halt Request 1 page 203.3KB
Regulatory Filings
2016-03-06 English
Half Yearly Report and Accounts 25 pages 889.7KB
Interim / Quarterly Report
2016-02-22 English
Company Update 1 page 22.7KB
Regulatory Filings
2016-02-14 English
Appendix 4C - quarterly 5 pages 39.3KB
Interim / Quarterly Report
2016-01-27 English